Where the act stands
The European Commission proposed the act in 2025, and the Parliament and Council reached a provisional agreement in 2026. Until it is formally adopted and published, its criteria are proposals, not law. This page will be updated when the final text is out.
What it would change in tenders
- Award criteria beyond lowest price for critical medicines, such as supply security and the reliability of the supply chain.
- More use of multi-supplier awards to avoid dependence on a single source.
- Weight for production or diversified sourcing within the EU, where the rules allow it.
- More joint and cross-border procurement between member states for some medicines.
What it means for bidders
Price will matter less in some tenders and supply evidence more. Bidders that can document where the active ingredient and finished product are made, how much stock they hold and how many sites qualify will score better. Those that only compete on price may see fewer winner-takes-all lots.
Several countries already apply similar rules: Germany's 2023 supply-security law requires an EU or EEA active-ingredient award for some antibiotic tenders, and France requires an environmental criterion in public contracts from August 2026.
How to prepare
Track which of your molecules are on the critical medicines list, how each buyer currently weights non-price criteria, and how often lots are already shared. RGS records award criteria and weightings per buyer, so the shift away from price-only awards is visible lot by lot.
Questions
Is the Critical Medicines Act in force?
No. A provisional agreement was reached in 2026, but the act still has to be formally adopted and published, and many provisions would apply only after a transition period.
Will medicine tenders stop being awarded on lowest price?
Not entirely. The act targets medicines judged critical. For other generics, price-only awards remain allowed, although many buyers are already adding supply-security criteria.